Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–93 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High-Dose Methylprednisolone Clear all
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Is Botox Effective in Relieving Pain From Knee Osteoarthritis?

NCT00279903
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Botulinum toxin type A (Btx-A), Cortisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

NCT03003520
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

NCT02029638
View directory record Official record
Conditions
Kidney Transplantation
Interventions
anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim
Biological · Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT01497496
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 4, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

NCT02763761
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 4, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

NCT02670707
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Cytarabine, Vinblastine/prednisone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

NCT00609739
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease

NCT00043147
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
beclomethasone dipropionate, methylprednisolone, prednisone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Oral Prednisolone Dosing in Children Hospitalized With Asthma

NCT00257933
View directory record Official record
Conditions
Asthma
Interventions
Prednisolone high dose, Prednisolone lower dose
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2010 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 4, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

MAGIC Ruxolitinib for aGVHD

NCT06936566
View directory record Official record
Conditions
Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions
Ruxolitinib, Methylprednisolone
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 4, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Steroid Treatment for Sickle Cell Pain Crisis

NCT00263562
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Steroid arm, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00549848
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 4, 2026, 2:42 AM EDT